How to smooth the patient access path to life-altering therapies

The newly approved PCSK9 inhibitors are a major advance in cholesterol-lowering drug therapy.  Gregory Curfman, MD and Editor in Chief of Harvard Health Publications, has said that this advanced therapy may just rewrite the script for treating patients with chronic high cholesterol. However, this same therapy promises to further raise the stakes in the ongoing match… read more

3 reasons to stop bashing biopharmaceutical manufacturers

“Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates vying for their respective party’s nomination for the 2016 presidential campaign take their positions. As Chris Seper reported via Matthew Herper at Forbes, Hillary Clinton and Bernie Sanders both identified the biopharmaceutical industry as their… read more

Key considerations in negotiating at-risk contracts

All healthcare stakeholders are aware the day is coming when pharma manufacturers will need to go at-risk in order to secure inclusion of their high-cost drugs in plan formularies.  This shouldn’t be viewed as simply a unilateral opportunity to force price concessions from manufacturers.  Rather, this is an opportunity to place patient outcomes squarely in… read more

Walk with Curant for cures and HIV treatment

We’ve talked about who we are: Curant Health is a team of healthcare experts who provide individualized, patient-centered services proven to deliver improved health outcomes. We’ve talked about what we bring to the healthcare table, including the improved outcomes we’ve demonstrated in HIV treatment and diabetes. Now it’s time to talk about ways we enjoy… read more

What biopharmaceutical manufacturers really want in network partnerships

As the creation of new drugs for chronic illness progresses, we ask ourselves certain questions when thinking from a biopharmaceutical manufacturer point of view: What key points do biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for distribution networks? What capabilities do they prioritize most highly? What factors benefit patients the most? Three metrics come… read more

The 80/20 Rule of Healthcare Spending

There’s an 80/20 rule when it comes to healthcare – 80% of healthcare cost comes from 20% of the populace, the chronically ill. According to the Deloitte Center for Health Solutions, healthcare spend in the United States is expected to eclipse $4 trillion this year. Take an estimated population of 319 million into consideration; that… read more

Media contact: Kristin Lindsey, Marketing Director at 866-437-8040, extension 253 or

Menu Title